[12] Patent
[11] Patent No.:GC0007624  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126240
Date of the Decision to Grant the Patent:19/Apr/2018

[21] Application No.:GCC/P/2004/3212

[22] Filing Date:9/2/2004

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
10/2/2003
60/445.818

[72] Inventors:1- CALLOWAY, James،2- BURKE, David J.،3- LEHRMAN, Sherwood Russ،4- BUCKLEY, Shaun E.،5- OCONNOR, Barbara Horsey

[73] Owner: Elan Pharmaceuticals, Inc., 800 Gateway Boulevard,California 94080, South San Francisco, USA

[74] Agent: Suleiman I. Al-Ammar Law Office

  

 

  

[51]IPC:
A61K39/395

[56] Cited Documents:

- WO 9822136 A2 (BOEHRINGER MANNHEIM GMBH)
28 May 1998
- WO 0212501 A2 (CENTOCOR INC) 14 August 1999
- US 5945098 A (SARNO MARIA ERLINDA C)
31 August 1999
 
Examiner: Ashwaq Hamed Al-Ghanami

[54] IMMUNOGLOBULIN FORMULATION AND METHOD OFPREPARATION THEREOF
[57] Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.
No. of claims: 20


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.